To this end, we compared RNA-seq on in vivo GSK126-treated KrasG12D/+;Trp53−/− and controls to those generated by limited ex vivo propagation of KrasG12D/+;Trp53−/− and KrasG12D/+;Trp53−/−;Eed−/− tumor cells. This evidence concerns the gene TP53 and neoplasm.